Navigation Links
Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials
Date:5/4/2010

GENEVA, SWITZERLAND, May 4 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

ANAVEX 2-73 is the first of a new class of drugs that target mitochondrial dysfunction thought to be caused by oxidative stress to modify Alzheimer's disease. This novel mechanism acts primarily via sigma receptors and is not a direct amyloid, nor tau, nor mitochondrial pore blockade mechanism. ANAVEX is developing non-amyloid focused approaches to disease modification in Alzheimer's disease and believes mitochondrial dysfunction caused by oxidative stress to be an underlying cause of Alzheimer's disease. By modulating ion channel signaling at a mitochondrial level, the company believes this class of patent-protected compounds may offer a new, disease-modifying approach in several neurological and neurodegenerative disorders.

Validated and standard animal models used to assess effects typically seen in Alzheimer's disease have been completed with excellent results. These studies were conducted in partnership with a leading Contract Research Organization, FORENAP Pharma EURL, which specializes in neuroscience and Alzheimer's disease research. The studies included oral and IV dosing and 28-day animal toxicity studies. Extensive studies were conducted in three species: rats, mice and dogs.

The company expects to submit the IND (Investigational New Drug) package to regulatory authorities in the near term.

"ANAVEX is delighted with the evidence generated in these extensive studies, including a favorable toxicology profile," said Dr. Cameron Durrant, Exec
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
2. Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
3. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
4. Anavex strengthens Board of Directors
5. Anavex advances drug candidate for treatment of Alzheimers disease
6. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
8. Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic
9. BMP Sunstone Reports Fourth Quarter and Full Year 2009 Financial Results
10. American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results
11. The Cancer Market Outlook To 2014: Competitive Landscape, Market Size, Pipeline Analysis and Growth Opportunities Now Available on ReportsandReports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... the Global Supply Chain of the biotech industry. ... SCM Innovation Awards, brought to you by the ... global organization of supply chain management professionals for ... given to stakeholders of the Biotech industry – ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... leading,supplier of virtual reality based training applications within the ... of the Board and,Goran Malmberg as President and CEO ... and brings with him a vast,array of experience in ... of several Swiss private and charitable foundations. Mr.,Ruscoe is ...
... Ltd. (ASX: PXL),CEO Dr Jenny Harry has been ... in Washington DC at the Partnering for Global ... Foundation and organised by Bio,Ventures in Global Health, ... http://pgh.bio.org/opencms/PGH/2008/program/program.jsp , The Forum follows a report ...
... researchers at the National Institute of Standards and ... in solution as they dart around in three ... plans to patent, will lead to a better ... and, ultimately, process control techniques to optimize the ...
Cached Biology Technology:Mentice AB Announces Leadership Changes Within Its Worldwide Operations 2The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 2The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 3All done with mirrors: NIST microscope tracks nanoparticles in 3-D 2
(Date:7/25/2014)... at the University of Houston, has written a ... development., "Introduction to Tissue Engineering: Applications and Challenges" ... field of artificial organ development. Metin Akay, founding ... served as a series editor on the book., ... books on the subject of growing artificial organs ...
(Date:7/25/2014)... research at the University of Adelaide has opened the way ... to powdery mildew. , In Australia, annual barley production is ... Powdery mildew is one of the most important diseases of ... have discovered the composition of special growths on the cell ... fungus into the leaf. , The research, by the ARC ...
(Date:7/25/2014)... (SB) is a complex congenital central nervous system ... of the neural tubes during the embryonic phase. ... and fecal incontinence and neurocognitive retardation. Such problems ... of life. Researchers at Ankara Physical Medicine and ... functional performance in children with SB, using the ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... FINDINGS: Short pieces of RNA, called microRNAs, control protein ... as messenger RNA or mRNA) to be disabled by ... Researchers have known that mammalian microRNAs control protein production ... wondered how much additional effects microRNAs impart by jamming ...
... OTO EXPO of the American Academy of Otolaryngology Head ... nose, and throat doctors in the world, will convene September ... 305 scientific research sessions, 594 posters, and several hundred instruction ... opportunity for journalists from around the world to cover breaking ...
... the cause of some of the most repugnant smells on ... forms actually has a sense of smell of its own. ... for the first time that bacteria have a molecular "nose" ... ammonia. Published today in Biotechnology Journal , their study ...
Cached Biology News:RNA snippets control protein production by disabling mRNAs 2RNA snippets control protein production by disabling mRNAs 3Bacteria breakthrough is heaven scent 2
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
... Biochain's plant total protein western ... rapidly screening tissue specific protein ... placenta total protein is included ... interblot control for comparison between ...
...
Biology Products: